• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lite Strategy Reports Fiscal 2026 Second Quarter Results

    2/17/26 8:50:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email

    SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 second quarter ended December 31, 2025.

    During the second quarter, the Company successfully launched its strategic initiative to transform its LTC holdings into a productive reserve asset, utilizing covered call options while also implementing a $25 million stock repurchase program.

    "The second quarter marked a pivotal shift in our evolution. We moved from simply accumulating LTC to launching our first active capital market operations to create value for stockholders and set Lite Strategy apart from other digital asset vehicles that focus solely on accumulation," said Jay File, CEO, CFO. "Unlike passive vehicles such as ETFs that offer singular exposure to digital assets, we believe our active strategies will benefit investors by potentially smoothing out market volatility while supporting the core Litecoin ecosystem."

    Mr. File further commented, "Our covered call options trading strategy implemented in the second quarter generated nearly $600,000 in gross premiums. This represents an important first step in our long-term strategy to transform our substantial Litecoin holdings into a productive reserve asset, instead of a static holding on our balance sheet."

    Fiscal 2026 Second Quarter Highlights

    • Active Treasury Management: Successfully launched the Company's covered call option program, generating approximately $600,000 in cash during the quarter. This cash stream demonstrates the Company's ability to generate yield on its LTC holdings, a key differentiator from passive investment vehicles.
    • Share Repurchase Program: Utilized proceeds from active treasury operations to commence the Company's $25 million stock repurchase program, reflecting management's commitment to disciplined capital allocation and focus on reducing the discount to NAV.
    • Pharmaceutical Operations: Initiation of pre-clinical research and development activities with its drug candidate pipeline in non-oncology disease indications for potential out-licensing or sale-related opportunities.
    • As of December 31, 2025, the Company held $8.8 million in cash and cash equivalents.

    Over the second half of fiscal 2026, Lite Strategy plans to continue to implement selective strategies in tandem with the experienced treasury management team at GSR, a leading crypto investment firm, to further execute on the share repurchase program and evaluate potential strategic investments or partnerships intended to expand the Company's operations and generate increasing stockholder value. Management believes this focused approach sets Lite Strategy apart from broader digital asset treasuries and the limited flexibility of ETFs, positioning the Company as a publicly traded vehicle that supports the institutional growth of the Litecoin network while providing stockholders with transparency and accountability.

    Litecoin Ecosystem Updates

    Following the 14th anniversary of its genesis block in October 2025, Litecoin is the second-oldest cryptocurrency (next to Bitcoin) and is engineered for speed, cost and privacy, with improved storage efficiency and a lifetime uptime record of 100%.

    "Litecoin is built on the same ‘hard money' principles as Bitcoin, developed with scarcity in mind and a defined cap of 84 million coins," Board Member Charlie Lee said. "The differentiating factor is that Litecoin is designed to be used as it is faster, cheaper, and optimized for global payments. Strategic network upgrades can future-proof Litecoin against concerns such as unwarranted snooping and quantum threats. For example, Litecoin's deployment of MWEB ensures that personal financial privacy remains a fundamental human right. Litecoin is not just a store of value, it is a better form of money that works for everyone, everywhere."

    To learn more about Lite Strategy, visit the Company's homepage at https://litestrategy.com.

    To learn more about Litecoin and its role in Lite Strategy's treasury, visit the About Litecoin page at https://litestrategy.com/about-litecoin/.

    For current holdings and related Company metrics, visit Lite Strategy's dashboard at https://litestrategy.com/dashboard/.

    About Lite Strategy, Inc. (LITS)

    Lite Strategy, Inc. (NASDAQ:LITS) is the first U.S. publicly traded company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, Inc., the Company has expanded its business model beyond its portfolio of drug candidates to focus on pioneering institutional-grade digital asset treasury strategies, in partnership with leading innovators across blockchain, finance, and technology.

    Forward-Looking Statements

    Certain information contained in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding our future actions, prospective products and activities, future performance or results. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, risk relating to being able to utilize our repurchase program to repurchase our shares in the market on attractive terms or at all, maintaining our current listing on Nasdaq, our ability to retain and attract senior management and other key employees, fluctuations in the market price of LTC and any associated impairment charges that we may incur as a result of a decrease in the market price of LTC below the value at which LTC is carried on our balance sheet, changes in the accounting treatment relating to our LTC holdings, our ability to achieve profitable operations, government regulation of cryptocurrencies and online betting, changes in securities laws or regulations, customer acceptance of new products and services including our LTC treasury strategy, the demand for our products and our customers' economic condition, the impact of competitive products and pricing, our proprietary rights, general economic conditions and other risk factors detailed in our annual report and other filings with the Securities and Exchange Commission. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

    Contacts:

    Justin J. File

    CEO, CFO

    858-898-0976

    [email protected] 

    Source: Lite Strategy, Inc.



    Primary Logo

    Get the next $LITS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy Reports Fiscal 2026 Second Quarter Results

    SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 second quarter ended December 31, 2025. During the second quarter, the Company successfully launched its strategic initiative to transform its LTC holdings into a productive reserve asset, utilizing covered call options while also implementing a $25 million stock repurchase program. "The second quarter marked a pivotal shift in our evolution. We moved from simply accumulating LTC to launching our first active capital market operat

    2/17/26 8:50:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company's digital asset treasury strategy as well as its pharmaceutical operations. "Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus," Board Member Charlie Lee said. "We recently celebrated Litecoin's 14th anniversary and its unblemished track record of reliability and uptime. LITS provides inv

    11/17/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    2/12/26 5:44:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Schornstein Alexander sold $946,137 worth of shares (690,611 units at $1.37), decreasing direct ownership by 16% to 3,674,862 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:15:14 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    2/17/26 8:50:24 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lite Strategy Inc.

    10-Q - Lite Strategy, Inc. (0001262104) (Filer)

    2/17/26 8:45:49 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    2/12/26 5:10:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care